Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily

Urology

Volumn 66, Issue 2, 2005, Pages 316-322

  Emberton, Mark ^a   Elhilali, Mostafa ^b   Matzkin, Haim ^b   Harving, Niels ^b   Van Moorselaar, Jeroen ^b   Hartung, Rudolf ^b   Alcaraz, Antonio ^b   Vallancien, Guy ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE SEVERITY; EXPERIENCE; HAZARD ASSESSMENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RELAPSE; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; SYMPTOM; URETHRA; URINARY TRACT DISEASE; URINE RETENTION;

ACUTE DISEASE; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; URINARY RETENTION; URINATION DISORDERS;

EID: 23744468937     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2005.03.024     Document Type: Article

References (14)

1. M. Emberton, G.L. Andriole, J. de la Rosette Benign prostatic hyperplasia disease of aging men Urology 61 2003 267 273
2. S.J. Jacobsen, D.J. Jacobson, C.J. Girman Natural history of prostatism risk factors for acute urinary retention J Urol 158 1997 481 487
3. C.G. Roehrborn, J.D. McConnell, M.M. Lieber Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia Urology 53 1999 473 480
4. C. Kolman, C.J. Girman, S.J. Jacobsen Distribution of post-void residual urine in randomly selected men J Urol 161 1999 122 127
5. J.D. McConnell, C.G. Roehrborn, K.M. Slawin Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients (abstract) J Urol 169 suppl 2003 332
6. S.A. Kaplan, C.G. Roehrborn, J.D. McConnell Baseline symptoms, uroflow, and post-void residual urine as predictors of BPH clinical progression in the medically treated arms of MTOPS trial (abstract) J Urol 169 suppl 2003 332
7. J.D. McConnell, C.G. Roehrborn, O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
8. P. van Kerrebroeck, A. Jardin, K.U. Laval Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia Eur Urol 37 2000 306 313
9. C.G. Roehrborn Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a randomized, placebo-controlled trial Urology 58 2001 953 959
10. C.G. Roehrborn, P. van Kerrebroeck, J. Nordling Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies BJU Int 92 2003 257 261
11. M. Emberton, K. Anson Acute urinary retention in men an age old problem BMJ 318 1999 921 925
12. AUA Practice Guidelines Committee AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendation J Urol 170 2003 530 547
13. M.J. Speakman, R.S. Kirby, A. Joice Guideline for the primary care management of male lower urinary tract symptoms BJU Int 93 2004 985 990
14. J.M.C.H. de la Rosette, G. Alivizatos, S. Madersbacher EAU guidelines on benign prostatic hyperplasia (BPH) Eur Urol 40 2001 256 263